Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TASR..........
News Release
TASER International Announces TASERNET Remote Area Denial and Facilities Protection System Concept
SCOTTSDALE, Ariz., Oct. 9, 2006 (PRIMEZONE) -- TASER International, Inc. (Nasdaq:TASR), a market leader in advanced electronic control devices, today announced that it will be presenting the TASER(r)-Remote Area Denial (T-RAD(tm)) concept along with a networking solution concept, TASERNET, at the Association for the United States Army (AUSA) Annual Meeting, October 9-11, 2006 in Washington, DC.
"T-RAD uses our life-saving TASER technology and combines this with an intelligent network and human control to provide a coordinated non-lethal area denial network," said Tom Smith, President of TASER International. "Technology like this is revolutionary in protecting soldiers and civilians in both military and non-military settings."
The T-RAD uses the proven TASER X26 core technology to provide an integrated, effective area denial and force protection. Suited for both military and non-military application, T-RAD is designed to be deployed at checkpoints, facility perimeters, embassies, airports, and other critical infrastructures and for demarcation of secure zones, such as improvised explosive device (IED) free areas.
"To integrate the network and create an operator friendly interface, we have teamed with AVAI, a company with an established history for providing facility networks, security, and control system integration," said Smith. "This will truly be a cost effective method of force multiplication that incorporates multiple proven technologies to create a powerful, new, non-lethal capability which is scalable for the U.S. military and security arenas," added Smith.
Although capable of operating autonomously, T-RAD units will be network ready, allowing the integration of multiple units with a command and control station such as TASERNET to provide comprehensive situational awareness of a T-RAD protected area, extended T-RAD operation via networked power, and man-in-the-loop oversight and control.
In August, TASER International announced the formation of a Senior Executive Advisory Board (SEAB) that will provide the company with a team of professionals with extensive military, homeland defense and law enforcement experience to advance the goal of supplying the military and government agencies with the benefits of TASER technology.
TASER International will be present at the AUSA Conference at booth #3754 at the Washington, DC Convention Center.
About TASER International, Inc.
TASER International provides advanced electronic control devices for use in the law enforcement, military, private security and personal defense markets. TASER(r) devices use proprietary technology to incapacitate dangerous, combative or high-risk subjects who pose a risk to law enforcement officers, innocent citizens or themselves in a manner that is generally recognized as a safer alternative to other uses of force. TASER technology saves lives every day, and the use of TASER devices dramatically reduces injury rates for police officers and suspects. For more information on TASER life-saving technology, please call TASER International at (800) 978-2737 or visit our website at www.TASER.com.
Note to Investors
This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of the 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by those sections. The forward-looking information is based upon current information and expectations regarding TASER International. These estimates and statements speak only as of the date on which they are made, are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results could materially differ from what is expressed, implied, or forecasted in such forward-looking statements.
TASER International assumes no obligation to update the information contained in this press release. TASER International's forward looking statements in this press release and future results may be impacted by the completion of the restatement of the Company's financial results for the first quarter of 2005 and the second quarter of 2005, risks associated with rapid technological change, new product introductions, new technological developments and implementations, execution issues associated with new technology, ramping manufacturing production to meet demand, litigation results from Company filed lawsuits and other litigation including lawsuits resulting from alleged product related injuries, media publicity concerning allegations of deaths occurring after use of the TASER device and the negative impact this could have on sales, product quality, implementation of manufacturing automation, potential fluctuations in quarterly operating results, adjustments to these amounts which may be reflected in our 10Q filing, competition, financial and budgetary constraints of prospects and customers, international order delays, dependence upon sole and limited source suppliers, negative reports concerning TASER device uses, governmental inquiries and investigations, medical and safety studies, fluctuations in component pricing, government regulations, variation among law enforcement agencies with their TASER product experience, TASER device tests and reports, dependence upon key employees, and our ability to retain employees. TASER International's future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-QSBs and its Annual Report on Form 10-KSB.
The statements made herein are independent statements of TASER International. The inclusion of any third parties does not represent an endorsement of any TASER International products or services by any such third parties.
CONTACT: TASER International, Inc.
Steve Tuttle, Vice President of Communications
Media ONLY Hotline: (480) 444-4000
Two IPO's this week that catch my eye:
The links below have all the info you need to start with, including prospectus links
APKT (works with SBC)
http://www.investorshub.com/boards/read_msg.asp?message_id=13868732
SAIC (billion dollar company - works with the government)
http://www.investorshub.com/boards/read_msg.asp?message_id=13868989
MLNM: Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
Friday October 6, 8:36 am ET
-- Study results formed basis of supplemental new drug application (sNDA) filing for relapsed mantle cell lymphoma --
CAMBRIDGE, Mass., Oct. 6 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today announced that the Journal of Clinical Oncology has published the final results of the PINNACLE trial, one of the largest multi-center studies ever done in the setting of relapsed mantle cell lymphoma (MCL). The results demonstrate the potential of VELCADE as treatment for relapsed MCL, an aggressive form of non-Hodgkin's lymphoma (NHL). The study, which provided the major source of data for the sNDA filing for VELCADE in relapsed MCL, was prepublished online in the September 25, 2006 Journal of Clinical Oncology and will run in the October 20, 2006 print issue. VELCADE for relapsed MCL is under Priority Review with the U.S. Food and Drug Administration (FDA) and a decision is expected by December 9, 2006.
"The publication in Journal of Clinical Oncology highlights the potential of VELCADE in the treatment of mantle cell lymphoma," said Deborah Dunsire, M.D., President and CEO, Millennium. "The study, one of several Phase II trials which consistently showed impressive response rates and duration of response, suggests that VELCADE may become a standard component of therapy in this disease."
Results of the study, which was undertaken with Millennium's co-development partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), showed a 33 percent overall response rate and an 8 percent complete response rate. Importantly, the median overall duration of response was 9.2 months, and 13.5 months in patients who achieved a complete response. These results are consistent with those of four investigator-initiated Phase II clinical trials where overall response rates of 30 to 40 percent with single-agent VELCADE were observed.
PINNACLE Study
In this prospective, single-arm study, 155 patients with relapsed or refractory MCL who had received a maximum of two prior therapies, received single-agent VELCADE 1.3mg/m2 twice weekly for two weeks every 21 days for up to one year. Patients achieving complete response, unconfirmed complete response or partial response received a median of 8 treatment cycles, and all patients in the study received a median of 4 cycles. Study results included:
* Overall response rate of 33 percent
* Complete response rate of 8 percent
* Median duration of response of 9.2 months; 13.5 months in patients
achieving a complete response
* Median time to progression of 6.2 months
* Median treatment-free interval of 13.8 months in patients achieving a
complete response
* Treatment was well tolerated. The most common non-hematologic adverse
events were fatigue, gastrointestinal events and peripheral neuropathy.
Hematologic toxicities were consistent with those previously seen with
VELCADE.
VELCADE currently is approved in the United States for the treatment of multiple myeloma (MM) patients who have received at least one prior therapy. To date, over 44,000 MM patients have been treated with VELCADE for MM worldwide, including clinical trials. Earlier this year, Millennium and co-development partner, J&JPRD, initiated a Phase III clinical trial with VELCADE in combination with rituximab in patients with relapsed or refractory follicular and marginal zone lymphoma.
About Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
NHL is the most common hematological cancer, the fifth leading cause of cancer death and the second fastest growing form of cancer in the U.S.(1) The prevalence of NHL is approximately 400,000 patients, 77,000 patients with follicular lymphoma and 10,000 with mantle cell lymphoma. There are approximately 54,000 new cases of NHL diagnosed per year, and 19,000 deaths are attributed to the disease annually(2,3).
MCL is an aggressive, rapidly progressive subtype of NHL, and is not curable with standard treatment. Because there is no generally accepted treatment approach and options are often limited, there is a growing need for new therapies. The average life expectancy for a patient with relapsed MCL is one to two years.
About VELCADE
VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.
Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.
In 331 patients who were treated with VELCADE in a Phase III study, the most commonly reported adverse events were asthenic conditions (61 percent), diarrhea (57 percent), nausea (57 percent), constipation (42 percent), peripheral neuropathy (36 percent), vomiting (35 percent), pyrexia (35 percent), thrombocytopenia (35 percent), psychiatric disorders (35 percent), anorexia and appetite decreased (34 percent), parasthesia (27 percent), dysesthesia (27 percent), anemia and headache (26 percent), and cough (21 percent). Fourteen percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (4 percent), neutropenia (2 percent), and hypercalcemia (2 percent). A total of 144 patients on VELCADE (44 percent) reported serious adverse events (SAEs) during the study. The most commonly reported SAEs were pyrexia (6 percent), diarrhea (5 percent), dyspnea and pneumonia (4 percent), and vomiting (3 percent).
VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in more than 75 countries worldwide. VELCADE also is approved in the European Union at first relapse.
For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical Company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Company's website is http://www.millennium.com.
This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com.
1. 2005, American Cancer Society, Inc., Surveillance Research.
2. SEER, SARGA, and Decision Resources (for growth rate) data.
3. Federico et al., BLOOD 95(3): 783-789; 2000.
Contacts:
Jennifer Snyder (media) Kyle Kuvalanka (investors)
(617) 444-1439 (617) 761-4734
http://biz.yahoo.com/prnews/061006/nef003.html?.v=69
Latest Stock To Watch: QLGC
QLogic Corp
Alert Price: $19.00
October 3, 2006
Recent Price Change: +3.8%
Oct 4 HOD: $19.73
InfinitiStocks issues a General Alert for QLogic Corp, a leading supplier of high performance storage networking solutions. On October 3, the company announced it intends to acquire SilverStorm Technologies, Inc, for $60 million in cash. QLogic CEO and president H.K. Desai, said, "The acquisition...will provide our customers with a leading edge, end-to-end solution...(and) will accelerate the ability of QLogic's OEM and channel partners to bring their solutions to market."
SilverStorm solutions power some of the world's largest supercomputers in Oil and Gas exploration, Automotive and Aerospace design, Financial Services, Bio Medical and Government Research. Customers include AMD, Canon, Chevron, Intel, Lockheed Martin, NASA, Riken Research Institute, Sandia National Laboratories, Sun Microsystems, Toyota, the US DoD, and Virginia Tech University. Russ Hawkins, SilverStorm CEO, stated, "SilverStorm's industry leading technology and QLogic's strong market presence will drive our expanded market share growth."
InfinitiStocks notes impressive analyst rankings for Q, including a recent JP Morgan upgrade to Overweight, and a Friedman Billings upgrade to Outperform. In addition to a favorable ROE (12.7%) and 51% profit margin, growth estimates for the current quarter are 29.4%, with 22.2% expected for the current year. Overall growth for the sector is rated at 12.5%.
Oct 3: QLogic to Acquire SilverStorm Technologies
Oct 3: QLogic to Announce Second Quarter Results
ELN: Health Canada grants approval of TYSABRI(TM) (natalizumab) for the treatment of multiple sclerosis following priority review
Wednesday October 4, 7:00 am ET
First new class of treatment in ten years shown to reduce rate of relapses by 68%(1)
MISSISSAUGA, ON, and DUBLIN, IRELAND, Oct. 4 /CNW/ - Biogen Idec Canada and Elan Corporation, plc announced today that following a priority review process, Health Canada has granted approval to TYSABRI(TM) (natalizumab) for the treatment of relapsing-remitting multiple sclerosis (MS).(2) TYSABRI is the first in a new therapeutic class of MS treatments (called selective adhesion molecule inhibitors) and has been shown to significantly reduce the rate of MS relapses as well as the progression of disability associated with the illness.(2)
ADVERTISEMENT
"TYSABRI has demonstrated a major reduction in relapses - by more than two-thirds - in clinical trials," said Dr. Paul O'Connor, AFFIRM Principal Investigator and Chief of Division of Neurology, St Michael's Hospital, Toronto. "Clinical trials that have looked at TYSABRI provide us with impressive evidence that it is a highly effective treatment for patients with MS."
A two-year, randomized, multi-centre, placebo-controlled, double-blind study (called AFFIRM) enrolled 942 patients and evaluated the effect of TYSABRI on the rate of clinical relapses and the progression of disability.(3) The results found that TYSABRI reduced the rate of clinical relapses by 68 per cent relative to placebo (p(less than)0.001), and the risk of sustained disability progression associated with MS by 42 per cent relative to placebo (p(less than)0.001).(4) Treatment with TYSABRI also resulted in sustained and statistically significant reductions in brain lesion activity as measured by magnetic resonance imaging (MRI) scans.(4)
In Canada, TYSABRI is indicated as monotherapy (i.e. single disease-modifying agent) for the treatment of patients with the relapsing-remitting form of MS to reduce the frequency of clinical relapses, to delay the progression of disability and to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans).(4) TYSABRI is administered once every four weeks by intravenous infusion.(5)
"TYSABRI's administration every four weeks also offers an additional benefit compared to the currently available MS therapies, some of which are injected as often as daily," said O'Connor.
MS attacks the protective myelin covering of the central nervous system, causing inflammation and often destroying the myelin in patches. In its most common form, relapsing-remitting MS, the illness is characterized as having well defined attacks followed by complete or partial recovery.(6) Relapsing-remitting MS makes up 75% of all MS cases in Canada.(7)
TYSABRI works by preventing the body's affected immune cells from migrating from the bloodstream into the brain where they can cause inflammation and potentially damage nerve fibers and their insulation.(8)
"Canada has one of the highest rates of MS in the world.(9) The approval of TYSABRI represents an important step forward for Canadians living with this disease," said Deanna Groetzinger, vice president of government relations and policy at the Multiple Sclerosis Society of Canada. "We are pleased there is another approved treatment option for Canadians with relapsing-remitting MS."
Paulette O'Leary, 36, has been living with MS for over half of her life. At one point a relapse left her without the use of her legs and numbness across the left side of her body. After other therapy options failed to help her, O'Leary opted to travel to the United States to receive TYSABRI treatments when it was approved by the Food and Drug Administration (FDA) in the US.
"My particular experience with MS was really terrible. The illness hit me very hard, and I went from my normal, everyday life, to feeling awful physically and emotionally. After one relapse I was left in a wheelchair," said O'Leary. "I eventually recovered, but did not escape some permanent residual disability. I tried several other therapies, but when I was on TYSABRI the results were quite impressive. For the first time in a long time, I could walk, I could do the things that I love to do - I could actually live my life again."
Independent safety evaluation published
Biogen Idec and Elan Corporation, plc voluntarily suspended TYSABRI from the US market and from all clinical trials in 2005. This was based on three cases of progressive multifocal leukoencephalopathy (PML).
A comprehensive, independent safety evaluation of more than 3,000 patients treated with TYSABRI was completed.
The detailed safety analysis of the data yielded no new confirmed cases of PML beyond the three previously reported. The results of this safety evaluation were published in the March 2006 issue of the New England Journal of Medicine.(10)
"The safety data analysis that was carried out by an independent panel of experts is reassuring. And getting an understanding of the benefit-risk profile of TYSABRI is an important step towards bringing this medicine to Canadian MS patients with confidence," said Dr. O'Connor. "Any treatment decision should be carefully evaluated by patients and their physicians."
Patients who are prescribed TYSABRI should enroll in the TYSABRI Care Program. The program ensures that appropriate physicians and infusion centres are able to prescribe or infuse the product.(11) The TYSABRI Care Program is a comprehensive program that will support the safe and effective use of TYSABRI by physicians and patients on an ongoing basis. It will optimize treatment through improved compliance, will standardize infusion treatment at clinics, will support safety through rigorous education and on-going surveillance, and, through support in areas like reimbursement and patient support, will ease the administrative burden of physicians and patients, allowing patients and their treatment team to focus on treating the illness.
AFFIRM and SENTINEL Phase III study design and adverse events
AFFIRM is a two-year, randomized, multi-center, placebo-controlled, double-blind study of 942 patients conducted in 99 sites worldwide (including ten sites in Canada with 101 MS patients), evaluating the effect of TYSABRI on the progression of disability as measured by at least a one-point increase on the Expanded Disability Status Scale (EDSS) sustained for three months, and the rate of clinical relapses. Progression of disability is a sustained change that has a long-term impact on a patient's functional and ambulatory performance. Patients in AFFIRM were randomized to receive either a 300 mg IV infusion dose of TYSABRI (n(equal sign)627) or placebo (n(equal sign)315) every four weeks.(4)
SENTINEL is a two-year, randomized, multi-center, placebo-controlled, double-blind study of 1,171 AVONEX(R)-treated patients in 123 clinical trial sites worldwide. AVONEX-treated patients who continued to experience disease activity were randomized to add TYSABRI (n(equal sign)589) or placebo (n(equal sign)582) to their standard regimen.(12)
The two-year adverse event profile in AFFIRM and SENTINEL were consistent with previously reported one-year results. Common events included headache, fatigue, urinary tract infection, depression, lower respiratory tract infection, limb and joint pain, and pharyngitis.(4),(12) The rate and incidence of infections in patients treated with TYSABRI and placebo-treated patients were similar. Serious infections occurred in 3.2 per cent and 2.6 per cent of patients treated with TYSABRI and placebo-treated patients, respectively.
Use of TYSABRI has been associated with an increased risk of progressive multifocal leukoencephalopathy (PML). PML can cause severe disability or death.(13)
Cases of PML included patients who were treated with TYSABRI for over two years or who received intermittent doses of TYSABRI over an 18-month period. In clinical trials, two cases of PML were observed in 1869 patients with multiple sclerosis treated for a median of 120 weeks; the third case occurred among 1043 patients with Crohn's disease after the patient received 8 doses. These patients were concomitantly exposed to immunomodulators (e.g. interferon beta) or were immunocompromised due to treatment with immunosuppressants (e.g. azathioprine).(14)
TYSABRI has also been associated with hypersensitivity reactions, including serious systemic reactions that occurred at an incidence of less than 1 percent of patients.(14)
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, unpredictable and potentially disabling disease of the central nervous system that affects approximately 55,000-75,000 Canadians.(11) Canada has one of the highest rates of MS in the world - it is estimated that three Canadians are newly diagnosed with MS every day.(10),(11) It is known as a disease of young adults, with onset, usually in women, between the ages of 15 and 40. It is characterized by symptoms such as vision problems, loss of balance, numbness, difficulty walking and even complete paralysis.(7)
About Biogen Idec
Biogen Idec (NASDAQ: BIIB - News) creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For press releases and additional information about the company, please visit www.biogenidec.com.
About Elan
Elan Corporation, plc (NYSE: ELN - News) is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit www.elan.com.
ATTENTION TELEVISION ASSIGNMENT/PRODUCERS:
B-roll available via satellite:
DATE OF FEED: Wednesday, October 4, 2006
TIME OF FEED: 2:00pm - 2:30pm EST
CO-ORDINATES: Anik F2 C, Transponder 3B
Audio subcarrier 6.2 and 6.8
Downlink frequency 3820 vertical
PATHFIRE Digital Media Gateway Coordinates:
DATE OF FEED: Wednesday, October 4, 2006
AVAILABLE AT: 10:00am EST
CO-ORDINATES: CNW tab, Video Provider A, Digital Media Gateway
STORY NUMBER: CNW06HAK9
If there are any difficulties with the satellite transmission, please call (416) 863-2112.
-------------------------------------------------------------------------
(1) TYSABRI Product Monograph 2006, page 18
(2) TYSABRI Product Monograph 2006, page 3
(3) Polman, Chris H. et al. The New England Journal of Medicine.
2006; 354: 899-910.
(4) TYSABRI Product Monograph 2006, page 3
(5) TYSABRI Product Monograph 2006, page 12
(6) Multiple Sclerosis Society of Canada website,
http://www.mssociety.ca/en/information/faq.htmNo.2 accessed September 21,
2006.
(7) http://www.mssociety.ca/en/information/types.htm, accessed on
September 21, 2006.
(8) TYSABRI Product Monograph, page 13-14
(9) Multiple Sclerosis Society of Canada Medical Update Memo, May 2, 2006
(10) Yousry, Tarek A. et al. The New England Journal of Medicine.
2006: 354: 924-933.
(11) Tysabri Product Monograph 2006, page 4
(12) Rudick, Richard A. et al. The New England Journal of Medicine.
2006; 354: 911-923.
(13) TYSABRI Product Monograph 2006, page 5
(14) TYSABRI Product Monograph 2006, page 7
For further information
Peter Gay, (416) 413-4732 (office), (416) 523-1420 (cell), peter.gay@hillandknowlton.ca, Hill & Knowlton Canada
Farah Meghji, (416) 413-4737 (office), (416) 894-3174 (cell), farah.meghji@hillandknowlton.ca, Hill & Knowlton Canada
--------------------------------------------------------------------------------
Source: Biogen Idec; Elan Corporation, plc
http://biz.yahoo.com/cnw/061004/tysabri_tm_approved.html?.v=1
WRLD - $55M stock repurchase
http://www.alphatradefn.com/story/2006-10-03/PRN/200610032051PR_NEWS_USPR_____NYTU273.html
LMIA - LMI Aerospace Signs $170 Million Contract With Gulfstream
Oct 3, 2006 7:00:00 PM
http://www.alphatradefn.com/story/2006-10-03/PRN/200610031900PR_NEWS_USPR_____CGTU105.html
Rural/Metro appoints new CFO
Tuesday October 3, 3:07 pm ET
Rural/Metro Corp. Tuesday announced the promotion of Kristine Beian Ponczak as senior vice president, chief financial officer and corporate secretary.
Ponczak, 42, brings more than 17 years of experience in all phases of financial management, including treasury, accounting, strategic planning and financial analysis. She has been on the Scottsdale company's executive management team for nine years and succeeds Michael Zarriello, who is no longer with the company.
Rural/Metro (NASDAQ:RURL - News) is a provider of ambulance and private fire protection services,
Published October 3, 2006 by The Business Journal
Hmmmm...is that good? Sounds ok to me...
" Prior to her promotion, Mrs. Ponczak, served as Vice President and Treasurer of Rural/Metro Corporation, managing the company's working capital strategies, financial planning and budgeting, operational performance measurement, financial risk management, corporate banking, investments, and taxation strategies."
Rural/Metro says CFO no longer with company, names replacement
Tue Oct 3, 2006 8:35am ET
TLM..........
Press Release Source: Talisman Energy Inc.
Talisman Acquires Fulmar and Auk Fields in the North Sea
Tuesday October 3, 9:00 am ET
CALGARY, ALBERTA--(MARKET WIRE)--Oct 3, 2006 -- Talisman Energy Inc. (TSX:TLM.TO - News) (NYSE:TLM - News) announced that its wholly owned subsidiary, Talisman Energy (UK) Limited, has reached agreement with Shell U.K. Limited and Esso Exploration and Production UK Limited, an ExxonMobil subsidiary, to acquire their combined 85.81% interest in the Fulmar unitized field (Blocks 30/11b and 30/16s) and a 100% interest in the Auk field (Blocks 30/16n and 30/16t) in the Central North Sea. The transaction is subject to normal consents, including UK Government approvals and the satisfaction of certain other conditions. Assuming successful completion of the transaction, Talisman is expected to assume operatorship later this year. The parties have agreed not to disclose the purchase price.
The transaction expands Talisman's existing Clyde core area assets in the Central North Sea and provides the opportunity for significant reserves and production growth. Talisman currently operates both the Clyde field (Talisman 95%) and Orion field (Talisman 93.7%), which, along with the Auk and Gannet fields, export volumes via the Fulmar production facilities. Talisman also has an existing 12.71% interest in the Fulmar field and has agreed to acquire Hess Limited's 1.48% interest in the Fulmar field, with the result that on completion of both transactions, Talisman will hold a 100% interest in the Fulmar field.
"This is a good business opportunity for Talisman and is a continuation of our successful development strategy in the North Sea," said Dr. Jim Buckee, President and Chief Executive Officer. "Production from the Auk and Fulmar interests is currently 8,000 barrels of oil per day and with redevelopment, there is significant upside. We believe there is an exciting opportunity to redevelop Auk, which has approximately 675 million barrels remaining oil in place. Successful application of horizontal wells in Auk has already been demonstrated and we intend to build on that experience to access further drilling opportunities in this large field and significantly increase reserves and production volumes.
"Fulmar is a vital production hub in this area, providing an export route for Auk, Clyde and Orion, as well as the Shell operated Gannet field. We expect that the combined Fulmar, Auk, Clyde and Orion operations will yield a number of operating efficiencies, which will help us to extend field life and enhance the ultimate recovery from all these assets."
Talisman Energy Inc. is an independent upstream oil and gas company headquartered in Calgary, Alberta, Canada. Talisman has operations in Canada and its subsidiaries operate in the North Sea, Southeast Asia, Australia, North Africa, the United States and Trinidad and Tobago. Talisman's subsidiaries are also active in a number of other international areas. Talisman is committed to conducting its business in an ethically, socially and environmentally responsible manner. The Company is a participant in the United Nations Global Compact and included in the Dow Jones Sustainability (North America) Index. Talisman's shares are listed on the Toronto Stock Exchange in Canada and the New York Stock Exchange in the United States under the symbol TLM.
Forward-Looking Statements
This news release contains statements that constitute forward-looking statements or forward-looking information (collectively "forward-looking statements") within the meaning of applicable securities legislation. These forward-looking statements include, among others, statements regarding: potential increases to recoverable reserves and production volumes; business plans for drilling, exploration and development; expected operating efficiencies, extensions to field life and recovery from oil and gas assets; potential field recovery factors; estimates of future production, including the estimated timing of future production; business strategy and plans or budgets; and other expectations, beliefs, plans, goals, objectives, assumptions, information and statements about possible future events, conditions, results of operations or performance.
Often, but not always, forward-looking statements use words or phrases such as: "expects", "does not expect" or "is expected", "anticipates" or "does not anticipate", "plans" or "planned", "estimates" or "estimated", "projects" or "projected", "forecasts" or "forecasted", "believes", "intends", "likely", "possible", "probable", "scheduled", "positioned", "goal", "objective" or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.
Various assumptions were used in drawing the conclusions or making the forecasts and projections contained in the forward-looking statements throughout this news release. Statements which discuss business plans for drilling, exploration and development assume that the extraction of crude oil, natural gas and natural gas liquids remains economic. The completion of any contemplated asset acquisitions is contingent on various factors, including favourable market conditions, the ability of the Company to negotiate acceptable terms of sale and receipt of any required approvals for such acquisitions.
Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties, which could cause actual results to differ materially from those anticipated by Talisman and described in the forward-looking statements. These risks and uncertainties include:
- the risks of the oil and gas industry, such as operational risks in exploring for, developing and producing crude oil and natural gas, and market demand;
- risks and uncertainties involving geology of oil and gas deposits;
- the uncertainty of reserves estimates and reserves life;
- the uncertainty of estimates and projections relating to production, costs and expenses;
- potential delays or changes in plans with respect to exploration or development projects or capital expenditures;
- fluctuations in oil and gas prices, foreign currency exchange rates and interest rates;
- the outcome and effects of completed acquisitions, as well as any future acquisitions and dispositions;
- the ability of the Company to integrate any assets it has acquired or may acquire or the performance of those assets;
- health, safety and environmental risks;
- uncertainties as to the availability and cost of financing and changes in capital markets;
- risks in conducting foreign operations (for example, political and fiscal instability or the possibility of civil unrest or military action);
- changes in general economic and business conditions;
- the effect of acts of, or actions against, international terrorism;
- the possibility that government policies or laws may change or governmental approvals may be delayed or withheld;
- results of the Company's risk mitigation strategies, including insurance and any hedging programs; and
- the Company's ability to implement its business strategy.
We caution that the foregoing list of risks and uncertainties is not exhaustive. Additional information on these and other factors which could affect the Company's operations or financial results are included: (1) under the heading "Risk Factors" in the Company's Annual Information Form; and (2) under the headings "Management's Discussion and Analysis - Risks and Uncertainties" and "Outlook for 2006" and elsewhere in the Company's 2005 Annual Report Financial Review. Additional information may also be found in the Company's other reports on file with Canadian securities regulatory authorities and the United States Securities and Exchange Commission.
Forward-looking statements are based on the estimates and opinions of the Company's management at the time the statements are made. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change except as required by law.
Oil and Gas Information
Talisman makes reference to production volumes in this news release. Where not otherwise indicated, such production volumes are stated on a gross basis, which means they are stated prior to the deduction of royalties and similar payments. In the U.S., net production volumes are reported after the deduction of these amounts. In this press release, Talisman refers to estimates of initial oil-in-place, which are inherently more uncertain than proved reserves and which U.S. oil and gas companies are prohibited from including in reports filed with the SEC.
Contact:
Contacts:
Talisman Energy Inc.
David Mann, Senior Manager,
Corporate & Investor Communications
(403) 237-1196
(403) 237-1210 (FAX)
Email: tlm@talisman-energy.com
Talisman Energy Inc.
Christopher J. LeGallais
Senior Manager, Investor Relations
(403) 237-1957
(403) 237-1210 (FAX)
Email: tlm@talisman-energy.com
Website: http://www.talisman-energy.com
--------------------------------------------------------------------------------
Source: Talisman Energy Inc.
It did mine !!!
That's HUGE !!
8-)
:) That should raise some eyebrows... :)
CHINA- CDC Games Signs Exclusive Agreement to Host The Lord of the Rings Online(TM) Game in China
Tuesday October 3, 7:30 am ET
BEIJING--(BUSINESS WIRE)--CDC Games, a business unit of CDC Corporation (NASDAQ: CHINA - News), today announced that it has signed an exclusive distribution license in China for the online game, The Lord of the Rings Online(TM): Shadows of Angmar(TM), the official online game based on the original literary works of J.R.R. Tolkien. The agreement is between CDC Games and the developer of the game, Turbine, Inc., a premier developer, publisher and operator of online subscription entertainment in the United States.
ADVERTISEMENT
The Lord of the Rings Online is one of the most highly anticipated online game titles planned for the worldwide markets in 2007. More than 200,000 players in the United States and Europe have already signed up for its Beta Program. CDC Games and Turbine, will work together to localize the game for the China market with an expected launch in 2007.
The Lord of the Rings Online is the first and only massively multiplayer online role-playing game (MMORPG) based on the literary works of J.R.R. Tolkien. It allows players to explore one of the most famous fantasy worlds of all time, fight the evil minions of the Dark Lord Sauron, and advance their heroes by adventuring through the vast reaches of Middle-earth. Gamers can adventure solo or choose from thousands of players online to forge their own fellowships as they face the hideous monsters and fight epic battles to defend Middle-earth.
"The Lord of the Rings is a phenomenal franchise, and the literary work has spawned a tremendous following the world over, achieving over US$2.9 billion in global box office receipts for the three films based on the books," said Fred Wang, chairman of CDC Games and independent director of CDC Corporation. "Many games have been inspired by the characters and stories set out by Tolkien, and we expect a tremendous response from loyal fans and gamers in China."
"We are excited to be partnering with CDC Games, one of the most successful online game companies in China," said Jeffrey Anderson, president and CEO of Turbine. "Based on their outstanding track record, we have high hopes for success with the Chinese gamers. We look forward to a long and successful partnership."
CDC Games has already established a strong foundation of loyal gamers with Yulgang, the company's current blockbuster online game in China. In Q2 of 2006, CDC Games reported registered players of Yulgang exceeding 30 million, and peak concurrent players exceeding 348,000. The Lord of the Rings Online will leverage this growing foundation of gamers and the nationwide network of distribution channels and server groups developed by CDC Games to support its operations.
"We are committed to delivering the best online gaming experience to our players," said Dr. Xiaowei Chen, CEO of CDC Games. "With that commitment in mind, we are very excited to bring The Lord of the Rings Online to China, not only because it represents a major global franchise, but also because Turbine has developed a truly beautiful and engaging game in which players will feel like they are part of Tolkien's world. Our partnership with Turbine underscores the tremendous success, attention to detail and transparency that our operations bring to the best game developers in the world as they seek to enter the massive China market."
About Turbine
Turbine, Inc. is a premier developer, publisher and operator of online games and entertainment and is headquartered in Westwood, Massachusetts. The company is one of the largest privately-held online games company in North America. Turbine's catalogue includes some of the most famous online entertainment brands, including Asheron's Call®, Dungeons & Dragons Online(TM): Stormreach(TM), and The Lord of the Rings Online(TM): Shadows of Angmar(TM). For more information on Turbine and its services, please visit www.turbine.com.
About Tolkien Enterprises
The Saul Zaentz Company d/b/a Tolkien Enterprises is the holder of worldwide motion picture, legitimate stage, merchandising, and other rights in J.R.R. Tolkien's literary works The Lord of the Rings and The Hobbit. Tolkien Enterprises has been producing and licensing films, stage productions and merchandise based on Tolkien's works for almost 30 years. Its headquarters are in Berkeley, California, and its website may be found at www.tolkien-ent.com.
About CDC Corporation
The CDC family of companies includes CDC Software focused on enterprise software applications and services, CDC Mobile focused on mobile applications, CDC Games focused on online games, and China.com focused on portals for the greater China markets. For more information about CDC Corporation (NASDAQ: CHINA - News), please visit www.cdccorporation.net.
About CDC Games
CDC Games is focused on building a diversified mix of online game assets and strategic alliances and is a business unit of CDC Corporation (NASDAQ: CHINA - News). CDC Games is one of the market leaders of online and mobile games in China with over 30 million registered players.
About CDC Mobile
CDC Mobile is the wholly owned subsidiary of China.com Inc and is focused on providing MVAS products to subscribers in China.
About CDC Software
CDC Software, The Customer-Driven Company(TM), is a provider of comprehensive enterprise software applications and services designed to help businesses thrive and become customer-driven market leaders. The company's industry-specific solutions are used by more than 5,000 customers worldwide within the manufacturing, financial services, health care, home building, real estate, and wholesale and retail distribution industries. CDC Software's product suite includes Pivotal CRM (customer relationship management), c360 CRM add-on products, industry solutions and development tools for the Microsoft Dynamics CRM platform, Ross ERP (enterprise resource planning) and SCM (supply chain management), IMI warehouse management and order management, Platinum China HR (human resource) and business analytics solutions. CDC Software is ranked number 18 on the Manufacturing Business Technology 2006 Global 100 List of Enterprise and Supply Chain Management Application vendors. For more information, please visit www.cdcsoftware.com.
Cautionary Note Regarding Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to risks and uncertainties and changes in circumstances. There are important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, including the following: the ability of CDC Games to localize, launch and operate The Lord of the Rings, the popularity of The Lord of the Rings in China, the ability of CDC Games to leverage the infrastructure and foundation of gamers in China, the loyalty of gamers in China. Further information on risks or other factors that could cause results to differ is detailed in filings or submissions with the United States Securities and Exchange Commission made by CDC Corporation in its Annual Report for the year ended December 31, 2005 on Form 20-F filed on June 21, 2006. All forward-looking statements included in this press release are based upon information available to management as of the date of the press release, and you are cautioned not to place undue reliance on any forward looking statements which speak only as of the date of this press release. The company assumes no obligation to update or alter the forward looking statements whether as a result of new information, future events or otherwise.
"The Lord of the Rings Online," "Shadows of Angmar," "Middle-earth," "The Lord of the Rings," and the names of the characters, events, items and places therein are trademarks or registered trademarks of The Saul Zaentz Company d/b/a Tolkien Enterprises under license to Turbine, Inc. Turbine and the Turbine logo are trademarks or registered trademarks of Turbine, Inc. in the United States and/or other jurisdictions. All other trademarks are the property of their respective owners.
Contact:
CDC Corporation
Investor Relations:
Craig Celek, 212-661-2160
craig.celek@cdccorporation.net
or
Articulate Communications for CDC Software
Media Relations:
Jennifer Buchhalter, 617.451.7788, ext. 16
jbuchhalter@articulatepr.com
--------------------------------------------------------------------------------
Source: CDC Software
http://biz.yahoo.com/bw/061003/20061003005571.html?.v=1
RICK was a sweet pick B...congrats!
RICK this AM printing $8.26 Thanks Serf for the heads up.
RE: RICK here at $4.61, was project 11 in Feb- We eventually closed it (april @ 6 bucks) when they had an investigation...fwiw
However, we've been following it since. Posts here thru Sept. It was noted to have an amazing 2 year chart by another board.
http://www.investorshub.com/boards/read_msg.asp?Message_id=10583879&txt2find=rickation.
Here comes $9.00.....
reminds me of one of my favorite " Monkees " tunes !!!
I alerted RURL on Sep 12 @ $7.30....it's quite an up and coming corp IMO. Check the news - 16 or 17 contracts since June. I don't know high it will go - Yahoo analysts say 12.00 but they're pumpers lol.
great call !!!!! what a rocket.................
RURL hit $8.90 today..that's all.
only have it on a WATCH list...........
RURL +0.06 0.69% 2,620 $8.79 RURAL/METRO CP
Wazzup Doc ??
EZ.....still in RURL? :) !
Earnings Announcements for Monday, October 2
Company Symbol EPS
Estimate* Time
Altran Technologies ALT.PA N/A Before Market Open
Great Southern Bancorp GSBC 0.55 Time Not Supplied
Innovo Group INNO N/A Time Not Supplied
Triple Crown Media, Inc. TCMI Time Not Supplied
Genzyme (nasdaq: GENZ) shares to cheap to pass up
http://www.forbes.com/2006/09/14/genzyme-campath-rebif-markets-equity-cx_pk_0914markets16.html?partn...
since its football season thought this biotech fantasy team might fit.
http://www.fool.com/news/commentary/2006/commentary06092514.htm?source=eptyholnk303100&logvisit=...
Elan Inks Alzheimer's Deal ( ticker eln ), this is one of my favorite plays..
http://www.thestreet.com/_yahoo/newsanalysis/pharmaceuticals/10311559.html?cm_ven=YAHOO&cm_c....
badknees
Understanding Cycles - The Key To Market Timing
Very good read:
http://www.investopedia.com/articles/technical/04/050504.asp
JAJO
An acronym representing the months January, April, July, and October.
These are the months in which many dividend paying companies declare dividends.
JAJO is also an option cycle.
http://www.investopedia.com/terms/j/jajo.asp
Quarterly Earnings Report
A quarterly filing made by public companies to report their performance. Included in earnings reports are items such as net income, earnings per share, earnings from continuing operations and net sales. These reports follow the end of each quarter. Most companies file in January, April, July and October.
An earnings report is a 'report card' of sorts for a public companies. It is through these reports that companies let shareholders know how well they have performed over the past time period. Most often the key metrics - net income and EPS - are weighed against the previous years' numbers. By analyzing this comparison, investors can begin to gauge the financial health of the company and whether or not it deserves their investment.
http://www.investopedia.com/terms/e/earningsreport.asp
Earnings Season
The months in which a majority of quarterly corporate earnings are released to the public.
Earnings season occurs in the month following the end of each quarter: January, April, July or October.
http://www.investopedia.com/terms/e/earningsseason.asp
Monday Effect
A theory that returns on the stock market on Mondays will follow the prevailing trend from the previous Friday. Therefore, if the market was up on Friday, it should continue through the weekend and, come Monday, resume its rise.
Some studies have shown a similar correlation. However, no one theory has been able to accurately explain the existence of the Monday Effect.
http://www.investopedia.com/terms/m/mondayeffect.asp
October Effect
A theory that postulates that stocks will tend to decline during the month of October.
Some investors may be nervous during October since the dates of some large historical market crashes occurred during this month. Black Monday, Tuesday and Thursday all occurred in October 1929, after which came the Great Depression. In addition, the great crash of 1987 occurred on October 19th, and saw the Dow plummet 22.6% in a single day. Today the October effect is considered mainly to be a psychological expectation rather than an actual phenomenon: most statistics go against the theory.
http://www.investopedia.com/terms/o/octobereffect.asp
YPNT seems to have picked up a big following today. It reached a high today of $0.99 but settled down ot $0.865. I think it is poised to take off.
Also, this is a very interesting posting that gives an idea as to what we might expect in the next earnings announcement:
http://www.investorshub.com/boards/read_msg.asp?message_id=13622800&txt2find=ypnt+
I expect that shortly YPNT will pre-announce their expectations for Q4 revenue and earnings as they have been in the past. I'm looking forward to seeing those numbers.
Mike
IPO-DIVX "thing of beauty" by CRAMER: Cramer said he's caught an "overlooked IPO" in DivX (DIVX - news - Cramer's Take). And he believes that the stock, which has increased almost 17% after its IPO, still has a lot of potential to make people money.
DivX is a company that makes software for video compression and decompression and does 18% of its business with Google (GOOG - news - Cramer's Take), Cramer said.
"We love Google and anything connected to Google," he said. "Soon there is going to be a bandwidth shortage, and that's why we believe DivX is sexy."
But that's not the only reason Cramer likes the stock. Sure, DivX may have "hotness potential," but the real reason he likes it is because of its fundamentals.
"I regard the numbers here as a thing of beauty," Cramer said.
DivX has a great business model, with 80% of its business coming from licensing fees. In addition, for 2005, DivX's gross margins were 89%. Additionally, in three straight years, DivX has doubled its revenue, he said.
The company has accelerated revenue growth, Cramer said. People missed getting into this stock because "it's a small company that is off the radar screen," said Cramer, who believes that DivX could be the next Akamai Technologies (AKAM - news - Cramer's Take
http://www.thestreet.com/_tscs/funds/madmoneywrap/10311391_2.html
AOB- American Oriental says unit gets $6 mln orders
Wed Sep 27, 2006 9:22am ET
Sept 27 (Reuters) - American Oriental Bioengineering Inc. (AOB.A: Quote, Profile, Research) on Wednesday said its recently acquired unit Guangxi Lingfeng Pharmaceutical Co. Ltd. received orders of over $6.0 million for its Jinji series of products which treat gynecological inflammations.
The plant-based pharmaceutical and nutraceutical products manufacturer said the products are expected to be delivered during the fourth quarter. (Reporting by Ankur Relia in Bangalore)
© Reuters 2006. All Rights Reserved.
AOB- American Oriental Bioengineering, Inc. Announces Strong Fourth Quarter Orders for GLP Products
Wednesday September 27, 8:58 am ET
-- As of September 24, the Company has received over $6 million in Initial Orders for GLP's Jinji Series of Products for the Fourth Quarter
-- The Company Anticipates a further Increase in Order Momentum for GLP Products
NEW YORK--(BUSINESS WIRE)--American Oriental Bioengineering, Inc. (AMEX: AOB - News), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, today announced GLP has received over $6.0 million in orders for its Jinji Series of products which are expected to be delivered during the fourth quarter.
ADVERTISEMENT
By leveraging AOB's marketing methodologies, its expanded distribution points and new advertising and marketing campaigns, AOB has begun to see an accelerating pace of business for GLP products. Specifically, the Company hired Ms. Ni Ping, a well known and recognized Chinese celebrity to endorse the Jinji Series of products which targets women's health. Additionally, AOB has implemented a comprehensive training program geared to further educating GLP salespeople and improving the overall level of sales execution. GLP's position in the market is strengthening as the products now have nationwide access to China through AOB's 100,000 distribution points.
"We are very pleased to see a further increase in revenue from our integration of GLP since April," commented Mr. Tony Liu, Chairman and Chief Executive Officer of AOB. "This level of order activity prior to the start of a quarter represents a record for GLP and we are comfortable with our manufacturing capacity to address further anticipated revenue growth. Strong demand for the products has necessitated AOB to manufacture during the China National Day Holiday, a time when many facilities are closed. We remain committed to establishing the Jinji Series as a top three brand in women's health in China and having the brand contribute significantly to AOB's total revenue."
About American Oriental Bioengineering Inc.
American Oriental Bioengineering, Inc. is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throughout China. For more information, visit http://www.bioaobo.com.
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:
Hayden Communications
Matt Hayden, 858-704-5065
--------------------------------------------------------------------------------
Source: American Oriental Bioengineering, Inc.
http://biz.yahoo.com/bw/060927/20060927005478.html?.v=1
3 PR's for VERIZON. My goodness:
Verizon Wireless Launches BroadbandAccess in Naples, Bradenton; Southwest Florida Linked With High-Speed Wireless Network, Services
Tuesday September 26, 3:27 pm ET
http://biz.yahoo.com/prnews/060926/nytu014.html?.v=60
Verizon Wireless Launches Wireless Broadband Network in Saint Augustine, Florida
Tuesday September 26, 3:27 pm ET
http://biz.yahoo.com/prnews/060926/nytu015.html?.v=60
Verizon Wireless Launches Wireless Broadband Network in Lakeland, Florida
Tuesday September 26, 3:27 pm ET
http://biz.yahoo.com/prnews/060926/nytu013.html?.v=62
UWN: Sure would like an opinion or two.
Though TPWR (a Pink and the way I ran into UWN) also owns an interest in American Racing, the Jeff Gural conceived operational owner of Tioga Downs and Vernon Downs race tracks, I'm betting the UWN pps will be the ultimate beneficiary of the two tracks successes.
UWN is down from a high of over $15 in early 2005 to a current pps of $5.18.
As of September 1, 2006, the registrant had 12,940,430 shares of common stock outstanding.
Here's some DD.
Executives tout Tioga Downs positive response
By My-Ly Nguyen
Houston-based Nevada Gold & Casinos Inc. said Thursday that Tioga Downs is expected to generate positive cash flow around October or November.
The racino has performed “very well” since video gaming was launched there July 4, company executives said during a first-quarter earnings conference call.
The “positive initial response” to Tioga Downs “reflects the success of our operational focus,” said Nevada Gold, which through a subsidiary, is a principal of Tioga Downs.
About Nevada Gold & Casinos
Nevada Gold & Casinos, Inc. (AMEX:UWN) of Houston, Texas is a developer, owner and operator of gaming facilities and lodging entertainment facilities in Colorado, California, and New York. The Company owns a 43% interest in the Isle of Capri-Black Hawk LLC, which owns Isle of Capri-Black Hawk and Colorado Central Station, both of which are in Black Hawk, Colorado. Colorado Grande Casino in Cripple Creek, Colorado is wholly owned and operated by Nevada Gold. The Company owns a 40% interest in the Tioga Downs Racetrack & Vernon Downs Racetrack in New York State and has a management contract for both facilities. The Company also works with Native American tribes in a variety of capacities. Native American projects consist of River Rock Casino in Sonoma County, California, a casino to be built in Tulsa, Oklahoma for the Muscogee (Creek) Nation, a casino to be built in Pauma Valley, California for the La Jolla Band of Luiseno Indians and a casino to be developed by Buena Vista Development Company, LLC in the city of Ione, California for Buena Vista Rancheria of Me-Wuk Indians. For more information, visit www.nevadagold.com.
Nevada Gold & Casinos, Inc. Awarded First Support Services Contract
HOUSTON, Sept. 18, 2006 (PRIMEZONE) -- Nevada Gold & Casinos, Inc. (AMEX:UWN) today announced that it has signed a definitive agreement to provide consulting support services to the La Jolla Band of Luiseno Indians. Under the terms of the agreement, Nevada Gold will advise and assist the Tribe with Phase I of the resort planned for its 10,000-acre reservation in Pauma Valley, California, which includes a 30,000-square-foot gaming facility, housing 350 -- 500 slot machines and eight table games.
Robert Sturges, Chief Development Officer, Nevada Gold & Casinos, Inc., commented, "This multi-million dollar agreement represents the first major consulting contract signed as part of our efforts to offer a new level of collaboration to Native American tribes. We hope that this agreement will be the first of many similar agreements, since we have received strong indications that there is a demand in Native American communities for this type of consulting service. By providing a full range of consulting capabilities, we enable tribes to leverage our development, marketing and management expertise to meet their operational objectives. The Company has always thought the Pauma Valley project represents a fantastic multi-phase development opportunity for the La Jolla Band of Luiseno Indians, and we are delighted to be moving forward with them on this exciting resort."
Tracy Nelson, Chairman of the La Jolla Band of Luiseno Indians, stated, "We believe this agreement provides us with a superior degree of flexibility and support, and are confident it will give the Tribe the tools we need to successfully manage the resort and gaming facilities autonomously over the long term. We are pleased to have finalized our agreement and look forward to working with Nevada Gold."
Nevada Gold & Casinos, Inc. Announces First Quarter Results
HOUSTON, Sept. 7, 2006 (PRIMEZONE) -- Nevada Gold & Casinos, Inc. (AMEX:UWN) today announced financial results for the first quarter ended July 30, 2006.
For the first quarter of fiscal 2007, net revenues decreased to $3.5 million compared to $3.7 million in the first quarter of fiscal 2006. The net loss for the first quarter of fiscal 2007 was $1.8 million compared to net income of $1.8 million in the first quarter of fiscal 2006. The net loss per diluted common share was $0.14, compared to net income per diluted common share of $0.13 in the prior year period. Financial results for the first quarter of fiscal 2007 include a $0.09 per diluted share loss due to $1.9 million in pre-opening costs at Tioga Downs and Vernon Downs. No gaming revenues are reflected in this number due to the fact that American Racing's quarter ended June 30, 2006.
Tioga Downs' racing facilities were opened on June 9, 2006 and the gaming area opened on July 4, 2006. Vernon Downs was in a pre-opening phase throughout the first quarter of fiscal 2007 and celebrated the grand opening of its racetrack on August 31, 2006.
H. Thomas Winn, Chairman and CEO of Nevada Gold & Casinos, Inc., commented, "We are very excited to have celebrated the grand opening of the Vernon Downs racetrack this past weekend, and believe the racing, lodging and entertainment facilities bring a new level of excitement to the Syracuse region. Tioga Downs has performed very well since it opened in July. We think the positive initial response to both of these projects reflects the success of our operational focus. Despite our short-term earnings challenges, we continue to feel confident that as we implement our growth and operating initiatives, both our existing projects and those in the pipeline leave the company well positioned to generate solid returns over the long term."
Financial Results
For the first quarter of fiscal 2007, net revenues decreased to $3.5 million compared to $3.7 million in the first quarter of fiscal 2006. The revenue decrease was primarily due to a $0.3 million decrease in net revenues from the Colorado Grande Casino-Cripple Creek during the first quarter.
Operating expenses increased to $4.2 million from $3.1 million primarily due to higher corporate expenses reflecting legal fees related to our successful litigation concerning Route 66 Casinos, LLC, as well as increased expenses related to expanded casino operations and the pursuit of additional gaming opportunities. Operating expenses before depreciation and amortization for Colorado Grande Casino decreased $0.2 million due to improved cost control which offset most of the revenue decrease.
The Company's equity in earnings from Isle of Capri-Black Hawk (IC-BH), the Company's joint venture with Isle of Capri Casinos, was $1.1 million for the first quarter ended July 30, 2006, compared to $2.3 million a year ago. The $1.2 million decrease in earnings year over year resulted in a $0.06 decrease in diluted earnings per share. IC-BH's first quarter adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), was $11.2 million in fiscal 2007 compared to $12.3 million in the prior year period. A reconciliation of EBITDA to operating income is provided in the attached financial statements.
The net loss for the first quarter of fiscal 2007 was $1.8 million compared to net income of $1.8 million in the first quarter of fiscal 2006. The net loss per diluted common share was $0.14, compared to net income per diluted common share of $0.13 in the prior year period. Diluted weighted average common shares outstanding in the first quarter were 12.9 million compared to 14.0 million in the prior year period.
During the first quarter of fiscal 2007, the Company repurchased 40,800 shares of common stock in the open market at an average price of $8.90 per share.
PHFB:Now has 49 live revenue-producing clients.
Total keeps climbing with the addition of the eight today.
http://www.phantomfiber.com/clients.php
It's going to take eye-popping revenues to move the pps, but that day isn't far away, IMO.
Phantom Fiber Upgrades WWTS' Mobile Platform and Eight New Gaming Operators Go Mobile
Tuesday , September 26, 2006 08:30 ET
TORONTO, ONTARIO -- (MARKET WIRE) -- 09/26/06 -- Phantom Fiber Corporation (OTCBB: PHFB), a wireless transaction enablement company specializing in the gaming and entertainment sector has upgraded World Wide Tele-Sports (Bet WWTS), a recognized leading betting service in the offshore gaming industry for over a decade, to its Advanced Wireless Platform. This week Phantom Fiber also launched eight more gaming sites on the latest version of its advanced mobile platform.
"WWTS has been a valued client for over two years and this upgrade is a significant and exciting addition to their existing service. As a result of this upgrade, their customized software platform can do much more than just take wagers; players can sign-up, make secure deposits and withdrawals, and enjoy the convenience of our multi-currency and multi-lingual function, using their mobile devices. Our numerous product features and unprecedented performance levels have also brought eight new operators to our platform and they, too, will profit from these benefits," said Jeff Halloran, President and CEO of Phantom Fiber. "Worldwide mobile wagering's popularity and adoption is rapidly growing and it has helped to advance our successful business efforts."
Phantom Fiber's strategy for the 2006-2007 football season has shown consistent results over the last few weeks. In time for this season, Phantom Fiber recently launched 16 new gaming sites on their mobile platform. Along with the WWTS upgrade, the Company has also launched an additional eight new operators to its mobile platform.
WWTS initially went live with Phantom Fiber in 2003 and was the first to promote the wireless betting platform. The Phantom Fiber system provides a seamless, single-account integration between the Internet betting platform and wireless devices. The recent upgrade will allow WWTS' clients to register their account and also make their secure deposits or withdrawals with their wireless devices.
Lawrence Rabie, Marketing Director for WWTS stated, "We've been on the cutting edge of wireless wagering for a while now and we see the value in continuing this trend by upgrading to Phantom Fiber's Advanced Wireless Platform. Their software platform is unmatched in the industry. Upgrading our application has added new features that will improve our customers' betting experience while continuing to provide them with an additional betting outlet that enables them access to their accounts securely, anytime and anywhere."
The new list of clients includes: Advantage Wagering (www.advantagewagering.com), Bet Bet (www.betbet.com), Cyber Sportsbook (www.cybersportsbook.com), Oasis Casino (www.oasiscasino.com), Las Vegas Sports Betting (www.lasvegassportsbetting.com), Sportbook (www.sportbook.com), Wager On Sports (www.wageronsports.com) and Quicksilver (www.betqs.com).
About Phantom Fiber Corporation
Phantom Fiber Corporation (OTCBB: PHFB) is the leading developer of wireless platform software in the gaming and entertainment sector that enables its customers to deliver high-performance applications across global communications networks to mobile users. Their wireless platform extends the rich multimedia content and user experience of existing Internet web sites securely and instantly to over 1,000 mobile devices including cellular phones and PDA's. This platform is already deployed to most segments of the global gaming industry and can also be used by enterprises seeking to implement high performance mobile applications in such markets as: remote medical record access; banking and brokerage applications; and, and logistics and distribution environments.
About BetWWTS
WWTS (World Wide Tele-Sports) is the foremost offshore gaming company offering both Internet and telephone wagering to its worldwide customers. Fully licensed and regulated in St. John's, Antigua since 1995, WWTS offers a complete range of online casino games and more than 150 betting options daily through its portfolio of companies and managed services.
Forward-Looking Statements:
Some statements in this release are "forward-looking statements" as that term is defined in Sections 27A of the Securities Act of 1933 as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934 as amended (the "Exchange Act"), and are subject to certain risks and uncertainties, including, but not limited to, economic conditions, competition, changes in laws and the demand for the company's goods and services, which could significantly affect anticipated future results. Actual results may differ materially from any forward-looking statements.
--------------------------------------------------------------------------------Contacts:
Phantom Fiber Corporation
Jordan Silverstein
The Investor Relations Group
(212) 825-3210
jsilverstein@investorrelationsgroup.com
Phantom Fiber Corporation
Maria Marmolejo
Director of Marketing
+ 506 254-8007
mariam@phantomfiber.com
For additional information please contact:
Lawrence Rabie
Marketing Director
lawrencer@betcorp.net
Source: Phantom Fiber Corporation
Crucell Announces WHO Prequalification for Quinvaxem(TM) Vaccine
Sep 26, 2006 5:10:00 AM
LEIDEN, NETHERLANDS -- (MARKET WIRE) -- 09/26/06 -- Leiden, The Netherlands, September 26, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that Quinvaxem(TM), its fully-liquid pentavalent vaccine co-developed with Novartis Vaccines and Diagnostics, has been granted 'prequalification' by the World Health Organization (WHO).
Following the awarding of licensure by the Korea Food and Drug Administration (KFDA) in March 2006, WHO prequalification is a final prerequisite for the combination vaccine to be made available to supranational purchasing organizations. Supranational organizations are major customers for combination vaccines, which are used in mass vaccination programs in developing countries.
http://www.infinitistocks.com/index-main.htm
Armor Holdings, Inc. Receives $183 Million M1114 Up-Armored HMMWV Components Order
Sep 26, 2006 7:30:00 AM
JACKSONVILLE, Fla., Sept. 26 /PRNewswire-FirstCall/ -- Armor Holdings, Inc. (NYSE: AH), a leading manufacturer and distributor of military vehicles, vehicle armor systems and life safety and survivability systems serving military, law enforcement, homeland security and commercial markets, announced today the receipt of a $183.2 million order for production of M1114 Up-Armored HMMWV supplemental armor components that increase IED protection levels. The Company stated that the new work is a modification to its existing multi-year contract with the U.S. Army Tank-automotive and Armaments Command. Production is to be completed in 2007 by the Armor Holdings Aerospace and Defense Group at its facilities near Cincinnati, Ohio.
http://www.infinitistocks.com/index-main.htm
excerpt......new China IPO = MR
NEW YORK (MarketWatch) -- Chinese medical-device company Mindray Medical priced above its range for its stock market debut on the New York Stock Exchange as the first of several initial public offerings on deck this week.
Mindray Medical International Ltd. (MR : mindray medical intl ltd spon adr MR0.00, 0.00, 0.0%) offered 20 million American depositary shares at $13.50 a share, above its range of $10 to $12.
CHINA..
Press Release Source: CDC Software
Mellon Asset Management Measures Significant Benefits During First Six Months with Pivotal CRM from CDC Software
Tuesday September 26, 8:09 am ET
Mellon Asset Management Generates Significant Financial Savings and Growth in New and Existing Business Opportunities
NORTHAMPTON, United Kingdom--(BUSINESS WIRE)--Pivotal Corporation, a leading Customer Relationship Management solution provider and the CRM division of CDC Software, the enterprise software company of CDC Corporation (NASDAQ: CHINA - News), today announced Mellon Asset Management, a provider of investment management products and services, has achieved significant financial savings estimated by Mellon to be worth GBP 500,000 in infrastructure and software and GBP 250,000 in support (a) in just two months following its implementation of the Pivotal Customer Relationship Management ("CRM") solution from Pivotal.
The Pivotal CRM solution is allowing Mellon Asset Management to consolidate its CRM infrastructure, software and support across its 12 asset management subsidiaries (b) including Standish Mellon Asset Management, Franklin Portfolio Associates and The Boston Company Asset Management. The subsidiaries will be able to manage customers' investments more profitably, provide enhanced levels of service and enable the organisations to make more informed business decisions.
Stephen Johns, head of eBusiness, Mellon Asset Management, commented: "It was important that our chosen CRM application would support our business and add value in meeting the needs of our asset management groups. We needed a system which would allow us to manage individual clients on an everyday level and also provide a single view of sales opportunities across the entire business."
He added: "Pivotal has been instrumental in leading such a successful project. Both teams have worked closely to coordinate the first phase of rollout across our sites. It was extremely important to capture the economies of scale in joining up the subsidiaries and consolidating areas such as infrastructure and software in line with compliance regulations."
Jason Rushforth, vice president, Financial Services CDC Software commented: "We are absolutely delighted to be working with Mellon Asset Management to provide an integrated CRM solution across its subsidiaries. It is a significant project that reaffirms our focus and unique expertise in the financial services sector. We have worked hard to understand Mellon's business objectives and we demonstrated our ability to deliver with numerous examples of similar financial services companies that are successfully using Pivotal CRM to address their key requirements. Through our knowledge and expertise in financial services, we've provided Mellon with a safe and speedy return on its investment."
Implemented in February 2006, the Pivotal CRM system is currently being used by more than 250 people. As a result of the success thus far, Mellon is in discussions regarding a further rollout to its global sales, marketing groups and investment subsidiaries later this year. Mellon is also planning expansion to include Mellon Global Investments, the international distribution subsidiary of Mellon Financial Corporation.
In addition to the expanded deployments within Mellon, the company is also planning to introduce new additional Pivotal modules and standard functionality to address broader business requirements. These plans include integration with Blackberry devices using the Pivotal Handheld module and the addition of Pivotal MarketFirst, a powerful eMarketing tool that will enable Mellon to streamline the planning, execution, measurement and optimisation of its marketing programs.
(a) Complete execution of plan to be implemented.
(b) As of 13/09/2006, not including joint ventures and other non-fully owned subsidiaries
About Mellon Financial Corporation
Mellon Financial Corporation is a global financial services company. Headquartered in Pittsburgh, Mellon is one of the world's leading providers of financial services for institutions, corporations and high net worth individuals, providing asset management, private wealth management, asset servicing, and payment solutions and investor services. Mellon has approximately $4.2 trillion in assets under administration or custody, and $870 billion under management (c). News and other information about Mellon is available at www.mellon.com.
(c) as of 30th June 2006, source Mellon Financial Corporation
About Pivotal Corporation
Pivotal Corporation, a software unit of CDC Corporation (NASDAQ: CHINA - News), is a leading provider of customer relationship management (CRM) applications to help organisations create superior customer experiences. Pivotal's CRM applications offer rich functionality, a highly flexible application platform, a full application suite, and best-in-class customisation abilities, all with a low total cost of ownership. Pivotal delivers software and services that are designed to produce meaningful increases in revenues, margins, and customer loyalty. More than 1,800 companies around the world have licensed Pivotal, including Farm Credit Services of America, Allianz Dresdner Asset Management, North Shore Credit Union, Morgan Keegan & Company, The Ziegler Companies, and Julius Baer Investment Management.
Pivotal's complete CRM software suite includes a powerful application platform and additional capabilities in analytics, mobile CRM, and partner management. For more information about Pivotal Corporation, please visit www.pivotal.com
About CDC Corporation
The CDC family of companies includes CDC Software focused on enterprise software applications and services, CDC Mobile focused on mobile applications, CDC Games focused on online games, and China.com focused on portals for the greater China markets. For more information about CDC Corporation (NASDAQ: CHINA - News), please visit www.cdccorporation.net.
About CDC Software
CDC Software, The Customer-Driven Company(TM), is a provider of enterprise software applications designed to help organizations deliver a superior customer experience while increasing efficiencies and profitability.
CDC Software's product suite includes the Pivotal CRM (customer relationship management), c360 CRM add-on products, industry solutions and development tools for the Microsoft Dynamics CRM platform, Ross ERP (enterprise resource planning) and SCM (supply chain management), IMI warehouse management and order management, Platinum China HR (human resource) and business analytics solutions.
These industry-specific solutions are used by more than 5,000 customers worldwide within the manufacturing, financial services, health care, home building, real estate, and wholesale and retail distribution industries. The company completes its offerings with a full continuum of services that span the life cycle of technology and software applications, including implementation, project consulting, outsourced business services, application management and offshore development. CDC Software is the enterprise software unit of CDC Corporation (NASDAQ: CHINA - News) and is ranked number 18 on the Manufacturing Business Technology 2006 Global 100 List of Enterprise and Supply Chain Management Application vendors. For more information, please visit www.cdcsoftware.com.
Forward Looking Statement
This press release includes "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, and includes statements relating to the ability of Pivotal to address the needs of its financial sector customers specifically Mellon Asset Management, the amount of financial savings from the implementation of Pivotal CRM and the ability of Mellon to manage customers' investments more profitably, provide enhanced levels of service and enable the organisations to make more informed business decisions with Pivotal CRM software. These statements are based on management's current expectations and are subject to risks and uncertainties and changes in circumstances. There are important factors that could cause actual results to differ materially from those anticipated in the forward looking statements including, among others: the conditions of the financial services industry; the continued ability of Pivotal solutions to address industry-specific requirements of financial services companies; demand for and market acceptance of new and existing enterprise software and services; development of new functionalities which would allow financial services companies to compete more effectively and changes in the type of information required to compete in the financial services business. Further information on risks or other factors that could cause results to differ are detailed in filings or submissions with the United States Securities and Exchange Commission made by our parent, CDC Corporation, including its Annual Report for the year ended December 31, 2005 on Form 20-F filed on June 21, 2006. All forward-looking statements included in this press release are based upon information available to management as of the date of the press release, and you are cautioned not to place undue reliance on any forward looking statements which speak only as of the date of this press release. The company assumes no obligation to update or alter the forward looking statements whether as a result of new information, future events or otherwise.
Contact:
CDC Corporation
Investor Relations:
Craig Celek, 212-661-2160
craig.celek@cdccorporation.net
or
Articulate Communications Inc.
Media Relations:
Jen Buchhalter, 617-451-7788, ext. 16
jbuchhalter@articulatepr.com
--------------------------------------------------------------------------------
Source: CDC Software
AERT C/C LINK for tomorrow: http://biz.yahoo.com/cc/3/72593.html
:) all part of the service.....
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |